Related Experiment Video

Updated: Jul 19, 2026

Subconjunctival Administration of Adeno-associated Virus Vectors in Small Animal Models
06:16

Subconjunctival Administration of Adeno-associated Virus Vectors in Small Animal Models

Published on: March 16, 2022

Antivascular endothelial growth factor agents and their development: therapeutic implications in ocular diseases

Peter K Kaiser1

  • 1Cleveland Clinic, Cleveland, OH, USA. pkkaiser@aol.com

American Journal of Ophthalmology
|October 3, 2006
PubMed
Abstract

Insights

Anti-vascular endothelial growth factor (VEGF) therapies show promise for treating age-related macular degeneration (AMD). Clinical trials demonstrate these novel treatments can improve vision in patients with this condition.

Area of Science:

  • Ophthalmology
  • Angiogenesis Research
  • Pharmacology

Background:

  • Angiogenesis, the formation of new blood vessels, plays a critical role in ocular diseases.
  • Vascular Endothelial Growth Factor (VEGF) is a key signaling protein that promotes angiogenesis.
  • Dysregulated angiogenesis contributes to vision-threatening conditions like age-related macular degeneration (AMD).

Purpose of the Study:

  • To review the role of angiogenesis and VEGF in ocular diseases.
  • To discuss the development, safety, and efficacy of anti-VEGF therapies.
  • To highlight current and emerging treatments for AMD targeting VEGF.

Main Methods:

  • Comprehensive literature analysis.
  • Review of current clinical trials for antiangiogenic agents.
  • Focus on treatments for age-related macular degeneration (AMD).

Main Results:

  • Novel antiangiogenic molecules targeting VEGF are utilized in AMD management.
  • Phase III clinical trials report significant vision improvement in AMD patients.
  • Emerging therapies demonstrate promising outcomes for this prevalent ocular disease.

Conclusions:

  • VEGF-targeted therapies represent a significant advancement in AMD treatment.
  • These treatments offer a promising therapeutic strategy for patients suffering from AMD.
  • Continued research into anti-VEGF agents holds potential for further improving ocular health.

More Related Videos

Encapsulated Cell Technology for the Delivery of Biologics to the Mouse Eye06:10

Encapsulated Cell Technology for the Delivery of Biologics to the Mouse Eye

Published on: March 30, 2020

Related Concept Videos

Regulation of Angiogenesis and Blood Supply01:24

Regulation of Angiogenesis and Blood Supply

Rapidly dividing tumors, embryos, and wounded tissues require more oxygen than usual, lowering the oxygen concentration in the blood. At low oxygen or hypoxic conditions, an oxygen-sensitive transcription factor called the hypoxia-inducible factor 1 or HIF1 is activated. HIF1 is a dimeric protein of alpha (ɑ) and beta (β) subunits.  Under optimal oxygen conditions, HIF1β is present in the nucleus while HIF1ɑ remains in the cytosol. HIF1ɑ is hydroxylated by prolyl hydroxylase and factor...
Open Angle Glaucoma: Treatment01:27

Open Angle Glaucoma: Treatment

In open-angle glaucoma, the iridocorneal angle remains open, but the trabecular meshwork becomes stiff, slowing down the outflow of aqueous humor. This causes a buildup of aqueous humor in the anterior chamber, leading to a sudden increase in intraocular pressure. The treatment for open-angle glaucoma focuses on reducing the elevated intraocular pressure by either decreasing the secretion of aqueous humor or increasing its outflow.
Drugs such as carbonic anhydrase inhibitors, α2- and...
Ophthalmic Drug Delivery Systems01:23

Ophthalmic Drug Delivery Systems

Ophthalmic drug delivery faces major limitations due to poor absorption across the corneal membrane. This process is primarily driven by diffusion and is influenced by two main factors: the physicochemical properties of the drug and tear drainage. Most ophthalmic drugs, such as pilocarpine, epinephrine, atropine, and local anesthetics, are weak bases. They are typically formulated at an acidic pH to enhance chemical stability. However, this leads to high ionization, reducing their ability to...
Mechanism of Angiogenesis01:10

Mechanism of Angiogenesis

Blood vessel formation starts early during embryonic development, around day 7. In the extraembryonic yolk sac, mesodermal precursor cells called hemangioblast proliferate and differentiate into angioblast. Angioblasts express vascular endothelial growth factor receptor 2 or VEGFR2, which binds VEGF-A, a proangiogenic factor, guiding blood vessel formation. VEGF signaling promotes angioblasts to form a blood island in the developing embryo. Angioblasts further differentiate, giving rise to...
Angle Closure Glaucoma: Treatment01:28

Angle Closure Glaucoma: Treatment

Angle-closure glaucoma, or closed-angle glaucoma, is an eye condition where the iris bulges out and blocks the iridocorneal angle, resulting in a buildup of aqueous humor and increased intraocular pressure. Immediate medical attention is necessary due to the sudden onset of symptoms. The treatment for angle-closure glaucoma includes short-term and long-term approaches. Short-term treatment involves using eye drops like pilocarpine to lower intraocular pressure by increasing aqueous humor...
Diabetic Retinopathy01:27

Diabetic Retinopathy

DefinitionDiabetic retinopathy is a microvascular complication of diabetes affecting the retinal blood vessels.Risk FactorsDiabetic retinopathy is present in almost all individuals with type 1 diabetes and more than 60% of those with type 2 diabetes after two decades of disease.The risk increases with poor glycemic control, hypertension, dyslipidemia, smoking, pregnancy, and puberty.Although cataracts and glaucoma are also more frequent in people with diabetes, retinopathy remains the leading...